Fred Hutch Cancer Center | Strategic Alliance Partners

May 24, 2023

Petros Grivas, MD, PhD, discusses findings from the primary analysis of cohort 3 of the phase 2 TROPHY U-01 trial in patients with metastatic urothelial cancer.

May 18, 2023

Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.

May 18, 2023

A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.

May 11, 2023

Dr Haffner explains distinguishing features between basal cell and adenocarcinoma of the prostate, findings from a genomics study of basal cell prostate carcinoma, and the challenges that arise when diagnosing and treating patients with this rare disease.

May 11, 2023

Shared insight on clinical trial data behind the intensification of maintenance immunotherapy in patients with metastatic urothelial carcinoma.

May 11, 2023

Centering discussion on several key clinical trials, expert panelists reflect on data behind maintenance avelumab in metastatic urothelial carcinoma.

May 04, 2023

A panel of four key opinion leaders discuss the role of maintenance therapy in metastatic urothelial carcinoma and how its use has impacted the treatment landscape.

May 04, 2023

A brief review of the appropriate number of chemotherapy cycles to utilize in the setting of metastatic urothelial carcinoma.

April 27, 2023

Switching their focus to the metastatic urothelial carcinoma treatment landscape, panelists identify cornerstone frontline treatment options.

April 27, 2023

A comprehensive review of novel treatment strategies in MIBC, including perioperative therapy, and respective ongoing clinical trials.

April 20, 2023

Expert panelists reflect on the molecular subtyping of patients to predict response to neoadjuvant therapy in Bladder BRIDGister.

April 20, 2023

Shared insight on the combination of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer in the HCRN GU 16-257 trial.

April 13, 2023

Focused discussion on the RETAIN BLADDER study, which explored the option to avoid cystectomy in patients with good response to systemic therapy.

April 13, 2023

Continuing their discussion on adjuvant therapy in in muscle-invasive bladder cancer, panelists identify the utility of minimal residual disease testing.

April 06, 2023

Stacey A. Cohen, MD, discusses the advantages and limitations of ctDNA as a biomarker for detecting minimal residual disease , real-world data on the relationship between fluctuating cfDNA levels and ctDNA detection, and how implementing ctDNA testing earlier to identify minimal residual disease could serve as a prognostic tool in clinical practice.

April 06, 2023

Centering discussion on several clinical trials, key opinion leaders reflect on the role of adjuvant therapy in muscle-invasive bladder cancer.

April 06, 2023

Expert perspectives on the evolving role of neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) with considerations for mainstay regimens.

March 30, 2023

Switching their focus to non-muscle-invasive bladder cancer (NMIBC), panelists identify the treatment armamentarium in this setting.

March 30, 2023

A bird’s eye view of treatment modalities in urothelial carcinoma covering systemic, surgical, and bladder preserving strategies.

March 23, 2023

A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.